Volition announces mars consortium clinical study suggests nu.q® h3.1. concentrations are closely associated with sepsis and organ failure

Peer reviewed clinical study for h3.1 biomarker published in critical care henderson, nev. , june 12, 2025 /prnewswire/ -- volitionrx limited (nyse american: vnrx) ("volition"), a multi-national epigenetics company, today announced the publication of a new clinical manuscript suggesting that the nu.q® h3.1 biomarker has the potential to inform clinical care in critically-ill intensive care unit (icu) patients in the assessment of sepsis, organ failure and subphenotypes.
VNRX Ratings Summary
VNRX Quant Ranking